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Abstract Salmon insulin-like growth factor-I (sIGF-I) expres-
sion is, as in mammals, induced by growth hormone (GH). To
elucidate the mechanism by which GH stimulates the transcrip-
tion of the IGF-I gene, we transiently transfected Hep3B cells
expressing the rat GH receptor with a sIGF-I promoter-
luciferase reporter construct. Activation of the construct by
GH added to the medium of the transfected cells was observed
when two specific transcription factors, STAT5 and HNF-1K,
were simultaneously overexpressed in these cells. This finding
demonstrates for the first time a GH-dependent activation of an
IGF-I promoter construct in an immortalized laboratory cell line.
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1. Introduction
Growth hormone (GH), a pleiotropic hormone secreted by
the adenohypophysis, exerts a variety of e¡ects on growth,
development and intermediary metabolism [1,2]. The
growth-promoting actions of GH, according to the longstand-
ing somatomedin hypothesis, are mediated by insulin-like
growth factor-I (IGF-I), which is secreted into the circulation
by the liver as a target of GH action [3]. The existence of this
hypothetical GH-IGF-I axis has been con¢rmed in numerous
experiments since then. A single intraperitoneal injection of
GH rapidly stimulates hepatic IGF-I gene transcription in
vivo in hypophysectomized rats [4]. In cell cultures, it has
been shown that GH strongly stimulates the transcription of
the two promoters of the mammalian IGF-I gene in primary
hepatocytes [5,6], as well as in Ob1771 mouse adipocytes en-
dogenously expressing IGF-I, of which the secreted IGF-I
probably serves local auto- and paracrine purposes [7,8].
Good progress has recently been made in the unraveling of
the signal transduction pathway triggered by GH binding to
its speci¢c membrane-bound receptor (GH-R). Following the
interaction between GH and GH-R, the homodimerized re-
ceptor associates with and speci¢cally activates the intracellu-
lar tyrosine protein kinase JAK2 [9]. Among other e¡ects,
stimulation of JAK2 results in the tyrosyl phosphorylation
of the GH-R and JAK2 itself, along with several members
of the signal transducer and activator of transcription
(STAT) family of transcription factors, STAT1, STAT3 and
STAT5 [10^13]. Upon phosphorylation, the STATs dimerize
and translocate from the cytosol to the nucleus, where they
recognize and bind to short palindromic Q-interferon-activated
sequence (GAS)-like DNA elements, thereby activating the
transcription of speci¢c genes. These new insights have re-
sulted in the identi¢cation of speci¢c GH response elements
in a number of genes. STAT1 and STAT3 have been found to
be involved in the GH-induced stimulation of the c-fos gene
promoter [10,14], while STAT5 is involved in the enhance-
ment of transcription of the L-casein gene by prolactin [15],
and of the serine protease inhibitor 2.1 (Spi2.1) [16,17] and
insulin [18] genes by GH. Although the role of GH as the
strongest secretagogue of IGF-I is undisputed at present, the
mechanism by which GH succeeds in stimulating the tran-
scription rate of the IGF-I gene is still unresolved.
In salmon, as in mammals, liver IGF-I mRNA and protein
levels become elevated after GH administration [19^21]. Since
the liver is the main endocrine source of circulating IGF-I,
studies on regulation of IGF-I expression have mainly been
focused on the role of liver-speci¢c and liver-enriched tran-
scription factors. Hepatocyte nuclear factor-1K (HNF-1K), a
liver-enriched transcription factor, was found to bind to and
strongly stimulate the activity of the salmon IGF-I gene pro-
moter [22], as has also been described for the homologous
IGF-I promoter P1 in the human IGF-I gene [23]. Neverthe-
less in salmon, as in mammals, the molecular link between
GH action and IGF-I upregulation has not been elucidated
to date. Dissection of the molecular mechanism involved is
hampered by the fact that IGF-I promoter activation by GH
is not observed in tumor-derived, de-di¡erentiated cells in
culture after transfection. This even holds true for cultured
cells still able to endogenously express IGF-I in signi¢cant
amounts (e.g. SK-N-MC and OvCar-3 cells). Possibly, these
laboratory cell lines lack su⁄cient amounts of GH-R or other
components of the GH signal transducing system to e¡ectuate
upregulation of the activity of the IGF-I promoter, be it en-
dogenous or brought into the cells by transfection. In the
present study, we tried to reconstitute the GH signaling path-
way leading from the GH-R to the IGF-I promoter in cul-
tured hepatoma-derived Hep3B cells and to identify the com-
ponents needed for GH-dependent promoter activation.
2. Materials and methods
2.1. Recombinant DNA constructs
The sIGF-I reporter construct p261M is derived from constructs
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p385D and p105M, which have been described previously [22]. The
HindIII-PvuII fragment of p385D was cloned into HindIII/PvuII di-
gested p105M, resulting in a promoter construct harboring the Hin-
dIII to MstI fragment of the sIGF-I promoter. The sIGF-I p163M
reporter construct was made by polymerase chain reaction (PCR)
ampli¢cation of the region between positions 3122 to +41 relative
to the transcription start site. To this end, we made use of a forward
oligonucleotide (5P-CGTTATTTAAGCTTGTGCCCAAAATCCT-
TAATGAATAATTTAGG-3P), extending from positions 3122 to
390 and containing a 5P-anchor sequence with a HindIII site (under-
lined), together with a reverse oligonucleotide (5P-GGCGTCTT-
CCATGGCAGGCTCGTTTTGG-3P) between positions +27 to +41
with a 5P-anchor sequence containing a NcoI site (underlined). The
PCR product was cloned into the HindIII/NcoI digested luciferase
reporter plasmid. The constructs were checked by dideoxy-sequencing
(Pharmacia T7 sequencing kit, Amersham Pharmacia Biotech, Uppsa-
la, Sweden). The reporter construct 6USpi-TK-Luc used as a positive
GH response control in transient transfection experiments has been
described previously [24]. Brie£y, it contains six tandem repeat copies
of the 45 bp GHRE-II element of the Spi2.1 gene promoter, extending
from 3145 to 3102, fused to a minimal basal TK promoter (3104 to
+51) and cloned in front of the ¢re£y luciferase reporter gene. The
expression plasmid encoding full-length rat GH-R, prRXba 6.5, was
constructed by cloning the BglI/BamHI cDNA fragment into the
SpeI/XbaI site of pcDNA I (Invitrogen, Leek, The Netherlands).
The 6USpi-TK-Luc and prRXba 6.5 constructs were kindly made
available to us by Dr. G. Norstedt (Stockholm). As an internal con-
trol for transfection e⁄ciency a plasmid containing the Rous Sarcoma
Virus promoter and enhancer directing the expression of the L-galac-
tosidase reporter gene (RSV-LacZ) was co-transfected with all con-
structs. The expression plasmids encoding full-length sheep STAT5
(pXM-MGF STAT5, [15]) and mouse hepatocyte nuclear factor-1K
(CMV-HNF-1K, [25]) were kindly provided by Dr. B. Groner (Frei-
burg) and Dr. G.R. Crabtree (Stanford), respectively.
2.2. Cell culture and transfection
The human hepatoma-derived cell line Hep3B (ATCC HB 8064)
was cultured in K-modi¢ed essential medium (K-MEM), supplemented
with 10% fetal calf serum, 100 IU/ml penicillin, 100 mg/ml strepto-
mycin and 300 mg/ml glutamine. The cells were grown at 37‡C in 5%
CO2. Hep3B cells were transfected using the calcium phosphate co-
precipitation method [26] at 45^50% con£uence in 6-well plates. Cells
were transiently transfected with 4 Wg of the reporter construct, 800 ng
of the expression vector encoding rat GH-R, and (unless stated di¡er-
ently) with 500 ng of the expression vector encoding full-length sheep
STAT5 and 400 ng of the mouse HNF-1K expressing construct. To
correct for variations in transfection e⁄ciency, 200 ng of RSV-LacZ
were included in each transfection. The total amount of DNA added
to the cells was kept constant at 6 Wg by the addition of carrier DNA.
Four h after addition of the precipitate, cells were shocked in 10%
dimethyl sulfoxide in serum-free K-MEM for 2 min. Fresh serum-free
K-MEM supplemented with 100 IU/ml penicillin, 100 mg/ml strepto-
mycin, 300 mg/ml glutamine and with or without 400 ng/ml human
GH (Norditropin, Novo Nordisk, Copenhagen, Denmark) was added.
The cells were harvested 16 h later, washed in phosphate-bu¡ered
saline and incubated for 15 min in 300 Wl of lysis bu¡er (100 mM
potassium phosphate bu¡er pH 7.8, 8 mM MgCl2, 1 mM dithiothrei-
tol, 15% glycerol, 1% Triton X-100). Luciferase measurements and
L-galactosidase assays were performed essentially as described
[27,28]. Brie£y, cellular debris was removed by centrifugation at
13 000Ug. Luciferase activity of 100 Wl of clear supernatant was meas-
ured after addition of 100 Wl of 0.5 mM luciferin (Sigma, St. Louis,
MO, USA) in lysis bu¡er supplemented with 0.5 mM ATP. Peak light
emission was recorded on a LUMAC/3M Biocounter M2010A.
L-Galactosidase activity of 30 Wl of the clear lysate was measured
after addition of 3 Wl 100UMg solution (0.1 M MgCl2, 4.5 M
L-mercaptoethanol), and 66 Wl of 1UONPG (4 mg/ml o-nitrophen-
yl-L-D-galactopyranoside in 0.1 M sodium phosphate, pH 7.5). After
incubation at 37‡C (usually 30 min to 1 h) and addition of 500 Wl of
Na2CO3, the intensity of the yellow color was determined by its opti-
cal density at 420 nm.
3. Results
3.1. Overexpression of STAT5 is not su⁄cient for
GH-dependent activation of the sIGF-I promoter
The e¡ect of GH on the promoter of the sIGF-I gene was
studied in Hep3B cells transiently transfected with sIGF-I
promoter-luciferase constructs (Fig. 1). Since Hep3B cells
lack signi¢cant levels of the GH-R, an expression plasmid
encoding the full-length rGH-R was brought into the cells
together with the promoter constructs by co-transfection.
After transfection, cells were incubated in the presence or
absence of 400 ng/ml GH for 16 h, after which the cells
were lysed and luciferase activities in the lysates were meas-
ured. As a control for GH activation the construct 6USpi-
TK-Luc, containing six tandem repeat copies of the GH re-
sponsive element of the Spi2.1 gene in front of the TK pro-
moter [24], was used. As can be seen in Table 1, GH treatment
of Hep3B cells transiently transfected with the 6USpi-TK-Luc
construct resulted in about 8-fold activation of the TK pro-
moter. However, no activation by GH was observed for the
sIGF-I construct p261M under identical experimental condi-
tions. Since the 6USpi-TK-Luc construct contains six copies
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Fig. 1. Schematic representation of the sIGF-I promoter constructs
p261M and p163M. The top part represents the genomic organiza-
tion of the 5P-untranslated region and ¢rst exon of the sIGF-I gene.
The double arrow indicates two transcription start sites which are
situated very close to each other. The single arrow indicates the
downstream transcription start site, to which position number +1 in
the sequence has been assigned. Black boxes represent the reported
HNF-1 site and the GAS-like consensus sequence.
Table 1
E¡ect of GH on promoter activity of the 6USpi-TK-Luc control plasmid and the p261M sIGF-I reporter construct
6USpi-TK-Luc p261M sIGF-I
3GH +GH 3GH +GH
No factor 1.00 þ 0.13 7.87 þ 2.33 1.00 þ 0.09 1.09 þ 0.22
STAT5 3.22 þ 0.76 388.52 þ 7.11 1.04 þ 0.20 1.39 þ 0.24
HNF-1 1.41 þ 0.01 3.05 þ 1.04 15.16 þ 0.71 18.06 þ 1.84
STAT5/HNF-1 3.61 þ 0.06 386.69 þ 34.38 15.15 þ 2.82 35.91 þ 3.51
Luciferase values measured for the basal promoter activities were in the range of 7500 light units for the 6USpi-TK-Luc construct and 600 light
units for the sIGF-I construct. The background value of the luciferase assay without addition of lysate is approximately 15 light units. The data
represent mean þ S.E.M. values of two independent duplicate experiments for the sIGF-I promoter construct and one duplicate experiment for the
6USpi-TK-Luc construct.
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of the GH response element and thus may be more sensitive
to GH treatment, we tried to enhance the sensitivity of the
system by overexpressing STAT5 in the transfected cells.
STAT5 overexpression caused the 6USpi-TK-Luc construct
to be activated much more e⁄ciently by GH, the 8-fold in-
duction being enhanced about 50 times to levels of around
400-fold activation (Table 1). Even in a system with such high
sensitivity for GH, no signi¢cant activation of the sIGF-I
promoter construct by GH was observed (Table 1).
3.2. GH-dependent activation of the sIGF-I promoter by
co-expression of STAT5 and HNF-1K
sIGF-I promoter activity is known to be stimulated by the
liver-speci¢c transcription factor HNF-1K [22]. Since e⁄cient
promoter activation often requires the synergistic e¡ect of two
or more transcription factors, we tested whether simultaneous
overexpression of STAT5 and HNF-1K resulted in sIGF-I
promoter activation to levels higher than those observed
with HNF-1K alone. In the presence of both HNF-1K and
STAT5, GH-dependent activation of the sIGF-I promoter
was indeed observed. In the absence of GH, the p261M
sIGF-I promoter construct (Fig. 1) is activated about 15-
fold by HNF-1K alone, and not by STAT5 alone. The combi-
nation of STAT5 and HNF-1K also resulted in 15-fold acti-
vation of the sIGF-I promoter, as observed with HNF-1K on
its own. When GH was added to the medium of the trans-
fected cells, the individual e¡ects of STAT5 and HNF-1K
separately did not change signi¢cantly, but their combined
presence resulted in about 35-fold activation of the sIGF-I
construct (Table 1). From this we conclude that the activity
of the sIGF-I promoter can be induced by GH in cultured
transformed cells after reconstruction of the GH signaling
system by co-expression of the GH-R, STAT5 and the liver-
speci¢c transcription factor HNF-1K.
As described previously, the level of activation of the sIGF-
I promoter by HNF-1K is rather variable, ranging from 16- to
34-fold [22]. This variation seems to be caused by slight di¡er-
ences in cell density and growth rate of the cells at the time of
transfection. However, within a single experiment further 2- to
3-fold activation by GH was always observed, to levels of 30
to 60 times higher than basal sIGF-I promoter activity. As
can be seen in Fig. 2A, the maximal activation by GH is
already observed when 0.1 Wg of STAT5 expression vector
was added to the transfection mixture, and essentially the
same results were obtained using 0.4 or 2.0 Wg of STAT5
expression plasmid. An independent experiment testing the
e¡ect of the level of HNF-1K expression shows that sIGF-I
promoter activity increases with the amount of HNF-1K vec-
tor in the transfection mixture, ranging from 0.02 to 0.4 Wg
(Fig. 2B). Higher amounts of HNF-1K expression vector did
not result in signi¢cantly higher activation.
3.3. A STAT5 recognition element is present in the
GH responsive construct
The GH-dependent potentiation of the activation of the
sIGF-I promoter by HNF-1K in the presence of STAT5 sug-
gests that a STAT binding element is present in the promoter.
Since the p261M construct still shows this e¡ect, the putative
binding site should be located within the 261 bp fragment of
the promoter present in p261M (Fig. 1). A GAS-like consen-
sus sequence (TTCTAAGAA) is indeed found within this part
of the promoter at positions 3159 to 3151, 50 bp upstream
of the HNF-1 binding site. In order to discriminate whether
the region responsible for the GH-dependent activation via
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Fig. 2. E¡ect of GH treatment in Hep3B cells transiently transfected
with the p261M sIGF-I promoter construct, the rGH-R construct,
and varying amounts of expression plasmids encoding STAT5 (pan-
el A) and HNF-1K (panel B).The basal promoter activity of p261M
was set at 1. The data in A and B represent the mean þ S.E.M. val-
ues of two independent experiments performed in duplicate.
Fig. 3. E¡ect of GH treatment of Hep3B cells transiently trans-
fected with the p163M salmon IGF-I promoter construct, the rGH-
R construct, and expression plasmids encoding STAT5 and/or
HNF-1K. The activation values represent the mean þ S.E.M. of two
independent duplicate experiments.
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STAT5 is indeed located upstream of the HNF-1 site in
p261M, we constructed a reporter plasmid, p163M, which
lacks the promoter region between positions 3220 to 3123
(Fig. 1). Thus p163M includes the HNF-1 binding site (3109
to 397) and the sequence downstream of this site to the MstI
site (+41), but not the GAS-like element (3159 to 3151).
HNF-1K is still able to activate the transcription rate of the
p163M construct, but neither in the absence nor in the pres-
ence of GH further activation was found when the cells were
co-transfected with the STAT5 encoding plasmid (Fig. 3).
From this we conclude that in addition to the HNF-1 binding
site a second element is involved in GH-dependent stimulation
of the sIGF-I promoter, and that the STAT binding consen-
sus sequence at positions 3159 to 3151 relative to the tran-
scription start site is the most likely candidate for this role.
4. Discussion
The DNA fragment upstream of the ATG start codon of
the sIGF-I gene has been shown to possess promoter activity
[29]. As in other IGF-I promoters, no TATA or CAAT box-
like elements have been detected in the sIGF-I promoter re-
gion, which may be the cause of the heterogeneous initiation
of transcription and the low basal activity observed for the
IGF-I promoters [30,31]. Multiple transcription start sites
have been identi¢ed in the sIGF-I gene [29], the three most
prominent of which are located within the ¢rst 250 nucleotides
upstream of the ATG start codon (see Fig. 1). RNA analysis
has revealed that the level of preproIGF-I mRNA is increased
6-fold in the liver of salmon injected with bovine GH [20]. The
mechanism by which GH regulates IGF-I expression has been
elusive, and the e¡ects of GH observed in intact animals and
in primary hepatocytes could not be reproduced using pro-
moter constructs in transfected tumor-derived cells in tissue
culture. New insights into the signal transduction pathways of
the GH stimulus, however, have resulted in the identi¢cation
of GH response elements in a number of genes, of which the
Spi2.1 gene is one of the most widely studied and most GH
sensitive examples. A 45 bp GH responsive element has been
identi¢ed in the 5P £ank of this gene [32]. Reporter constructs
containing six to eight repeats of the 45 bp element linked to a
heterologous promoter (e.g. the thymidine kinase (TK) pro-
moter), are clearly sensitive to GH regulation, especially in
cells stably transfected with a GH-R encoding expression con-
struct [32,33]. This sensitivity is mediated by STAT5, binding
synergistically to two GAS-like elements within the 45 bp
fragment [34]. In view of these ¢ndings, we tested whether
combined overexpression of GH-R and STAT5 in Hep3B cells
would lead to induction of responsive promoters by GH. For
the 6USpi-TK-Luc construct, harboring six copies of the 45
bp GH response element, this was indeed the case. In con-
trast, the activity of the sIGF-I promoter was hardly in£u-
enced by GH even under these conditions. However, by con-
comitant expression of HNF-1K we were able to demonstrate
for the ¢rst time a distinct stimulating e¡ect of GH on a
sIGF-I promoter construct. The already rather strong activa-
tion caused by HNF-1K was enhanced 2- to 3-fold by GH
stimulation in STAT5 overexpressing cells. The need for syn-
ergistic binding of transcription factors to two or more se-
quence elements in order to activate a promoter is frequently
observed. In fact, the natural promoter of the Spi2.1 gene,
harboring only one copy of the 45 bp GH response element,
is also activated only very moderately by GH in a transient
transfection system. Here, a second element, the so-called
GAGA box at about 60 nt downstream of the STAT5 binding
sites, seems to play an important role in vivo. It has been
found that a high level of Spi2.1 gene transcription correlates
with hypersensitivity of the promoter to DNaseI and maximal
occupancy of the GAGA box. Based on these and other ¢nd-
ings, a mechanism of Spi2.1 gene activation has been sug-
gested in which GH-dependent chromatin remodeling caused
by the recruitment of GAGA box binding proteins is the ¢rst
compulsory and presumably predominant step [34]. A similar
mechanism may well play a role in GH-induced activation of
the sIGF-I gene promoter. Conceivably, HNF-1K and possi-
bly other (even by itself non-stimulating) members of the
HNF-1 family may bind to the response element in the pro-
moter, and thereby enable GH-activated STAT5 to also bind
to its response element. Such a model could explain the ob-
served rapid stimulation of transcription of the sIGF-I gene in
the liver upon injection of GH into the intact animal, since the
activation of STAT5 by JAK2 in the hepatocytes is an imme-
diate response to the GH signal.
The GH-IGF-I axis is a well conserved feature in vertebrate
evolution, suggesting that the factors involved in this regula-
tory mechanism are equally well conserved. Although our
studies were performed using mouse HNF-1 and sheep
STAT5 in a human liver-derived cell line, studies on the cor-
responding transcription factors in ¢sh indicate that both fac-
tors are indeed highly conserved during evolution. The Atlan-
tic salmon (Salmo salar L.) HNF-1 cDNA clone shows high
conservation with respect to other species of the homeo do-
main, the POU domain, and the dimerization domain. Of the
three transcription activation domains, two out of three (ADI
and ADIII) are also conserved, albeit to a lesser extend. The
salmon HNF1 protein is able to bind speci¢cally and with
equivalent a⁄nities to the rat and salmon albumin promoters
[35]. A putative STAT molecule has been identi¢ed in the
channel cat¢sh (Ictalurus punctatus), and binds to the mam-
malian interferon-gamma activation site, a known motif of
mammalian STAT binding [36]. From these and other studies,
STAT molecules were concluded to have been highly con-
served in vertebrate evolution.
Acknowledgements: The authors wish to thank Drs G.R. Crabtree, B.
Groner, and G. Norstedt for their kind gifts of recombinant DNA
constructs used in this study. This work was supported in part by a
grant from the HCM Programme of the European Commission
(ERBCHRX-CT94-0556).
References
[1] Jones, J.I. and Clemmons, D.R. (1995) Endocr. Rev. 16, 3^34.
[2] Carter-Su, C., Schwartz, J. and Smit, L.S. (1996) Annu. Rev.
Physiol. 58, 187^207.
[3] Salmon, W.D. and Daughaday, W.H. (1957) J. Lab. Clin. Med.
49, 825^836.
[4] Bichell, D.P., Kikuchi, K. and Rotwein, P. (1992) Mol. Endocri-
nol. 6, 1899^1908.
[5] Thomas, M.J., Kikuchi, K., Bichell, D.P. and Rotwein, P. (1994)
Endocrinology 135, 1584^1592.
[6] Le Stun¡, C., Thomas, M.J. and Rotwein, P. (1995) Endocrinol-
ogy 136, 2230^2237.
[7] Doglio, A., Dani, C., Fredrikson, G., Grimaldi, P. and Aihaud,
G. (1987) EMBO J. 6, 4011^4016.
[8] Kamai, Y., Mikawa, S., Endo, K., Sakai, H. and Komano, T.
(1996) J. Biol. Chem. 271, 9883^9886.
FEBS 21538 15-2-99
I. MetoŁn et al./FEBS Letters 444 (1999) 155^159158
[9] Argetsinger, L.S., Campbell, G.S., Yang, X., Witthuhn, B.A.,
Silvennoinen, O., Ihle, J.N. and Carter-Su, C. (1993) Cell 74,
237^244.
[10] Meyer, D.J., Campbell, G.S., Cochran, B.H., Argetsinger, L.S.,
Larner, A.C., Finbloom, D.S., Carter-Su, C. and Schwartz, J.
(1994) J. Biol. Chem. 269, 4701^4704.
[11] Gronowski, A.M. and Rotwein, P. (1994) J. Biol. Chem. 269,
7874^7878.
[12] Gronowski, A.M., Zhong, Z., Wen, Z., Thomas, M.J., Darnell
Jr., J.E. and Rotwein, P. (1995) Mol. Endocrinol. 9, 171^177.
[13] Smit, L.S., Meyer, D.J., Billestrup, N., Norstedt, G., Schwartz, J.
and Carter-Su, C. (1996) Mol. Endocrinol. 10, 519^533.
[14] Campbell, G.S., Meyer, D.J., Raz, R., Levy, D.E., Schwartz, J.
and Carter-Su, C. (1995) J. Biol. Chem. 270, 3974^3979.
[15] Wakao, H., Gouilleux, F. and Groner, B. (1994) EMBO J. 13,
2182^2191.
[16] Le Cam, A., Pantescu, V., Paquereau, L., Legraverend, C., Fau-
connier, G. and Asins, G. (1994) J. Biol. Chem. 269, 21532^
21539.
[17] Wood, T.J., Sliva, D., Lobie, P.E., Pircher, T.J., Gouilleux, F.,
Wakao, H., Gustafsson, J.A., Groner, B., Norstedt, G. and
Haldosen, L.A. (1995) J. Biol. Chem. 270, 9448^9453.
[18] Galsgaard, E.D., Gouilleux, F., Groner, B., Serup, P., Nielsen,
J.H. and Billestrup, N. (1996) Mol. Endocrinol. 10, 652^660.
[19] Roberts, C.T., Graham, D.E., Seelig, S., Berry, S., Gabbay,
K.H., Rechler, M.M. and Brown, A.L. (1986) J. Biol. Chem.
261, 10025^10028.
[20] Cao, Q.-P., Duguay, S.J., Plisetskaya, E., Steiner, D.F. and
Chan, S.J. (1989) Mol. Endocrinol. 3, 2005^2010.
[21] Duguay, S.J., Swanson, P. and Dickho¡, W.W. (1994) J. Mol.
Endocrinol. 12, 25^37.
[22] Kulik, V.P., Kavsan, V.M., Van Schaik, F.M.A., Nolten, L.A.,
Steenbergh, P.H. and Sussenbach, J.S. (1995) J. Biol. Chem. 270,
1068^1073.
[23] Nolten, L.A., Steenbergh, P.H. and Sussenbach, J.S. (1995) Mol.
Endocrinol. 9, 1488^1499.
[24] Wood, T.J., Sliva, D., Lobie, P.E., Goullieux, F., Mui, A.L.,
Groner, B., Norstedt, G. and Haldosen, L.A. (1997) Mol. Cell.
Endocrinol. 130, 69^81.
[25] Kuo, C.J., Conley, P.B., Hsieh, C., Franke, U. and Crabtree,
G.R. (1990) Proc. Natl. Acad. Sci. USA 87, 9838^9842.
[26] Graham, F.L. and Van der Eb, A.J. (1973) Virology 52, 456^467.
[27] de Wet, J.R., Wood, K.V., DeLuca, M., Helinski, D.R. and
Subramani, S. (1987) Mol. Cell. Biol. 7, 725^737.
[28] Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) in: Molec-
ular Cloning: A Laboratory Manual, Cold Spring Harbor Labo-
ratory Press, Cold Spring Harbor.
[29] Koval, A., Kulik, V., Duguay, S., Plisetskaya, E., Adamo, M.L.,
Roberts Jr., C.T., LeRoith, D. and Kavsan, V. (1994) DNA Cell.
Biol. 13, 1057^1062.
[30] Jansen, E., Steenbergh, P.H., LeRoith, D., Roberts Jr., C.T. and
Sussenbach, J.S. (1991) Mol. Cell. Endocrinol. 78, 115^125.
[31] Adamo, M.L., Ben-Hur, H., Roberts Jr., C.T. and LeRoith, D.
(1991) Mol. Endocrinol. 5, 1677^1686.
[32] Yoon, J.B., Berry, S.A., Seelig, S. and Towle, H.C. (1990) J. Biol.
Chem. 265, 19947^19954.
[33] Enberg, B., HultheŁn, A., Moºller, C., Norstedt, G. and Francis,
S.M. (1994) J. Mol. Endocrinol. 12, 39^46.
[34] Simar-Blanchet, A.E., Legraverend, C., Thissen, J.P. and Le
Cam, A. (1998) Mol. Endocrinol. 12, 391^404.
[35] Deryckere, F., Byrnes, L., Wagner, A., McMorrow, T. and Gan-
non, F. (1995) J. Mol. Biol. 247, 1^10.
[36] Rycyzyn, M.A., Wilson, M.R., BengteŁn, E., Warr, G.W., Clem,
L.W. and Miller, N.W. (1998) Mol. Immunol. 35, 127^136.
FEBS 21538 15-2-99
I. MetoŁn et al./FEBS Letters 444 (1999) 155^159 159
